High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease.
about
Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathyAllopurinol therapy improves vascular endothelial function in subjects at risk for cardiovascular diseases: a meta-analysis of randomized controlled trials.Allopurinol and the risk of atrial fibrillation in the elderly: a study using Medicare data.Serum uric acid and target organ damage in essential hypertensionEarly onset hyperuricemia is a prognostic marker for kidney graft failure: Propensity score matching analysis in a Korean multicenter cohort.Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort studyCardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs.Relationship of serum uric Acid level and angiographic severity of coronary artery disease in male patients with acute coronary syndrome.Serum uric acid is associated with left ventricular hypertrophy independent of serum parathyroid hormone in male cardiac patients.Targeted antioxidant treatment decreases cardiac alternans associated with chronic myocardial infarctionEffects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.Effects of Allopurinol on Arterial Stiffness: A Meta-Analysis of Randomized Controlled TrialsAllopurinol and the risk of stroke in older adults receiving medicareThe possible antianginal effect of allopurinol in vasopressin-induced ischemic model in rats.Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data.Technical assessment of whole body angiography and cardiac function within a single MRI examination.A Randomized Controlled Trial of Allopurinol in Patients With Peripheral Arterial Disease.Gender-related differences in the association between serum uric acid and left ventricular mass index in patients with obstructive hypertrophic cardiomyopathy.Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study.Allopurinol reduces the risk of myocardial infarction (MI) in the elderly: a study of Medicare claims.Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study.An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.Safety and effect of high dose allopurinol in patients with severe left ventricular systolic dysfunction.Hyperuricemia and the Prognosis of Hypertensive Patients: A Systematic Review and Meta-Analysis.Impact of allopurinol on risk of myocardial infarction.Drug Therapy for Stable Angina Pectoris.Xanthine oxidase inhibitors in ischaemic heart disease.Opposing effects of sodium intake on uric acid and blood pressure and their causal implication.Impact of Left Ventricular Hypertrophy on Survival in Chronic Obstructive Pulmonary Disease.Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study.Nitroso-redox imbalance affects cardiac structure and function.As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.An Open-Label Dose-Finding Study of Allopurinol to Target Defined Reduction in Urate Levels in Hemodialysis Patients.Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.Uric Acid and New Onset Left Ventricular Hypertrophy: Findings From the PAMELA Population.Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial.Cardiac and renal protective effects of urate-lowering therapy.Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study): rationale and design of the MET-REMODEL study.Uric Acid and Left Ventricular Hypertrophy: A Potentially New Modifiable Target?
P2860
Q27001165-5D54B4B8-2584-4591-B9EC-7005ECCE30FFQ30248398-F4452588-729C-45B7-BB21-0BF2F970BE17Q31095161-96DE9141-2FB8-4F19-89F7-1EB76C8FD246Q33583766-FC53CA56-F31D-48EC-9EAC-08B2A684D022Q33632726-CAC88EC8-A922-4016-9289-DD2CF37E195CQ33712386-81BDF64E-BECD-4FAA-8011-B9416B5404F1Q34453236-83F2A500-61E1-4790-802C-B7D999EAB6DFQ34658500-D793E3DA-E582-4F8E-BD80-AB88C77F8DADQ35067870-10E500BC-32C3-41B1-B610-A9C026F50AEEQ35102331-5ADC7E32-329D-4D70-B058-0F527CB5DF94Q35627898-6C2367B0-BAEA-450E-8C69-F9F04217F16CQ35998065-0FB0C44F-515F-42E8-992C-F2AD5EEEB6EFQ36125528-3FB63D80-42AA-46C8-941F-6DFFB646A0CBQ36162034-8BCF16EE-8450-4BA8-B012-B6151F377558Q36317644-F1BEA560-0E16-4FBA-89D8-D573A6CAD442Q36506223-9D9B1029-01AC-4134-B573-D6C2CCDC2600Q36547734-EF90535E-B74E-493F-A957-1424F5CF4530Q36769535-72BF5634-FF25-4845-AA02-4FECD4A5880FQ37097189-99761074-97F2-4F4A-9896-4AC0FA66623BQ37251800-EDA7441E-C1D4-41B2-A3A5-4111F3913F19Q37274458-470EA010-E106-4345-B2FA-72EBF6220332Q37515580-EB8B81D3-DB2A-44F2-82A1-322AEBD33259Q37641297-B7F6AE9A-0CEE-4443-8407-3F177816C663Q38652335-EDEB327C-3D8C-4E4D-9AA9-8E3EEB75FC74Q38849699-9D091D08-6815-4734-BCB9-15F81C1ABF10Q39033643-734F895B-D2B0-4DD8-81A5-AAD936571872Q39102158-043DB07D-B356-4BDD-87F3-1C3F102737C1Q39324330-E1EEFB01-4B1F-497A-86AD-9C4C16369FB7Q40431657-11623311-AEEA-436F-8700-D710FA78BCC9Q41142817-0C65F046-AC25-448A-9E58-C4BED50EF52BQ41507487-18ED0BC0-5CAC-4FEA-A678-682888CF81FBQ42668752-4D9DC08F-E175-4005-B00A-20A98B5D398BQ45823744-EAC472AD-6B90-4D16-9FFC-953B159858BBQ46650318-73671A4D-68B2-4CF1-89C8-5E72E37531E5Q47594590-9EB10C7D-1976-480B-B9C3-67398384DF9FQ48640386-B1A787E8-0719-49DF-8A76-EBAAE427C1C9Q48799743-0FB8173F-9126-432A-AB25-806F04A0667EQ49616077-B1FCF6DD-C7E3-4528-B1FF-BE6096425973Q51310417-E632631E-F266-4043-9641-EA5B3EF85DF8Q53570093-994363B4-EDED-40FE-89B8-AB98FEB371D3
P2860
High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
High-dose allopurinol reduces ...... s with ischemic heart disease.
@en
High-dose allopurinol reduces ...... s with ischemic heart disease.
@nl
type
label
High-dose allopurinol reduces ...... s with ischemic heart disease.
@en
High-dose allopurinol reduces ...... s with ischemic heart disease.
@nl
prefLabel
High-dose allopurinol reduces ...... s with ischemic heart disease.
@en
High-dose allopurinol reduces ...... s with ischemic heart disease.
@nl
P2093
P1476
High-dose allopurinol reduces ...... s with ischemic heart disease.
@en
P2093
Awsan Noman
Benjamin R Szwejkowski
J Graeme Houston
Jacob George
M Adnan Nadir
Stephen J Gandy
Sushma Rekhraj
P304
P356
10.1016/J.JACC.2012.09.066
P407
P577
2013-03-01T00:00:00Z